The incidence of meningococcal disease in Navarra and Spain is determined for the 1991-1997 period, with a detected density of incidence of 5.46 per 100,000 in the 1987-1991 period. In Navarra the incidence in the 1991-1997 period was of 3.26 per 100,000 inhabitants, of which 1.91 per 100,000 corresponded to serogroup B, 0.77 per 100,000 corresponded to serogroup C, and a rate of 0.57 per 100,000 were non-grouped. During the year 1997 (weeks 1 to 35) the accumulated incidence in the period of MD serogroup C was of 0.38 per 100,000 (2 cases), the Ratio of Rates Navarra/Spain was 0.21. Considering that the last case of MD occurred in week 8, in an adult woman of 39 years and nonexistence of serogroup A in Navarra, it can bi concluded that there is no justification for a strategy of mass or routine vaccination with respect to meningococcus C.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.23938/ASSN.0628 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.
Lancet
March 2025
Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address:
Background: Invasive meningococcal disease is a devastating public health problem for the African meningitis belt. We assessed the safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, Y, W, and X (NmCV-5) relative to a licensed, quadrivalent meningococcal conjugate vaccine (MenACWY-TT) when co-administered with routine childhood vaccines at ages 9 months and 15 months.
Methods: In this single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial, children aged 9-11 months who had completed their local infant Expanded Program on Immunization (EPI) vaccines were recruited at the Centre pour le Développement des Vaccins in Bamako, Mali.
Emergence of high-level penicillin-resistant Neisseria meningitidis harboring ROB-1-type β-lactamase gene in Japan.
J Infect Chemother
March 2025
Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan.
While antimicrobial resistance in Neisseria meningitidis, the causative agent for invasive meningococcal disease (IMD), is rare, some meningococcal isolates in Japan were resistant to ciprofloxacin and penicillin (PCG). Among 290 meningococci isolated from 2003 to 2020 in Japan, four PCG resisitant (PCG) meningococci were found but showed the minimum inhibitory concentration (MIC) with 0.5 μg/mL at a maximum due to mutation in penA gene that encodes penicillin-binding protein 2 (PBP2).
View Article and Find Full Text PDFMarket and Non-Market Productivity Losses Associated with Invasive Meningococcal Disease in the USA.
Pharmacoeconomics
March 2025
GSK, Wavre, Belgium.
Background And Objective: Invasive meningococcal disease (IMD) is an uncommon but serious disease associated with a risk of death and severe long-term sequelae, impacting both patients and their caregivers. Productivity losses due to IMD have not previously been comprehensively evaluated in the USA. This study evaluated both market and non-market productivity losses to better estimate the economic burden of IMD in the USA.
View Article and Find Full Text PDFTwo New Kindreds with Complete Factor D Deficiency.
Eur J Immunol
March 2025
Department of Immunology, Assistance Publique- Hôpitaux de Paris (AP-HP), Georges Pompidou European Hospital, Paris, France.
Inborn deficiencies of the alternative pathway (AP) of the complement system have been associated with life-threatening infections, mainly by encapsulated bacteria. Complete factor D (FD) deficiencies have been reported in only seven families in the literature. We report two new cases of biochemically and genetically confirmed complete FD deficiency, including the first in a Down syndrome patient.
View Article and Find Full Text PDFGeographical and temporal variations of serogroups and clonal types of involved in culture-confirmed invasive meningococcal disease in Canada, 2015-2023.
J Med Microbiol
March 2025
Vaccine Preventable Bacterial Diseases, Science, Reference and Surveillance Directorate, National Microbiology Laboratory Branch, Pubic Health Agency of Canada, Winnipeg, Manitoba, Canada.
Invasive meningococcal disease (IMD) is a nationally notifiable illness in Canada due to its potential severity and transmissibility. Vaccination strategies differ by province/territory and are informed by changes in the antigenic characteristics of circulating strains. Though IMD statistics are tracked at a provincial/territorial level, there is a lack of published data characterizing trends in the epidemiology of this disease at a national level.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!